Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biologics’ Big Bang: Novel BLAs Balance Breakthroughs And ‘Biobetters’

Executive Summary

Both FDA’s biologics and drug centers posted historic BLA approval counts in 2014, combining to clear 21 novel biologics. The class is split between medical breakthroughs and “biobetters” offering incremental improvements, illustrating the maturation of the biotech industry.

You may also be interested in...



Keeping Track: Novel Approvals Break Annual Records

The latest drug development news and highlights from our FDA Performance Tracker.

NME Half-Year Report: CDER Sets Strong Foundation With 14 Novel Approvals

More than twice that number of novel agent applications have user fee goals coming up in the second half of 2015, putting FDA in good position to maintain its streak of high annual NME counts.

Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals

As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel